Meeting
2018 ASCO Annual Meeting
Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases.
Authors
Li Zhang
DFCI at St. Elizabeth Medical Center, Boston, MA
Li Zhang , Kathryn P. Gray , Grace Shaw , Carolyn Evan , Edoardo Francini , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5049)
DOI
10.1200/JCO.2018.36.15_suppl.5049
Abstract #
5049
Poster Bd #
276
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Bone modifying agents in veterans with castration-resistant prostate cancer.
First Author: Jordan Bauman
Poster
2020 Genitourinary Cancers Symposium
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.
First Author: Edoardo Francini
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Incidence of skeletal-related events in men with castration-resistant prostate cancer.
First Author: Alison Tse Kawai
Poster
2012 ASCO Annual Meeting
Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer.
First Author: Karim Fizazi